Nimbus Picks Janssen’s Tummino for Chief Scientific Officer Post

Nimbus Therapeutics has appointed Peter Tummino to serve as its chief scientific officer. Tummino comes to the Cambridge, MA, company from Johnson & Johnson (NYSE: [[ticker:JNJ]]) subsidiary Janssen, where he was vice president and global head of lead discovery. His experience also includes multiple roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]). Nimbus, which uses computational science to discover and develop drugs, counts Genentech and Celgene (NASDAQ: [[ticker:CELG]]) among the partners developing drugs discovered with the company’s technology.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.